Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + nab-paclitaxel + tegafur + gimeracil + oteracil
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of sintilimab (an anti-PD-1 monoclonal antibody), nab-paclitaxel (a novel taxane formulation), and S-1 (a combination of tegafur, gimeracil, and oteracil). Sintilimab blocks the interactions between PD-1 and its ligands, enhancing T-cell immune responses against tumor cells. Nab-paclitaxel is an albumin-bound formulation of paclitaxel with advantages including less hypersensitivity reactions, neurotoxicity, and neutropenia compared to conventional paclitaxel. S-1 is an oral fluoropyrimidine that combines tegafur (a prodrug of 5-fluorouracil), gimeracil (which inhibits 5-FU degradation), and oteracil (which reduces gastrointestinal toxicity). This triplet regimen is being investigated for various cancers including gastric cancer and biliary tract carcinoma.
- Brand names
- TyvytAbraxaneTeysuno
- Other names
- sintilimab + nab-paclitaxel + S-1
02
Targets
TS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)OPRT (Orotidine 5'-phosphate decarboxylase)MicrotubulePDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + nab-paclitaxel + tegafur + gimeracil + oteracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + nab-paclitaxel + tegafur + gimeracil + oteracil.